Sign in
Taking peoplePhase 4

A Randomised Controlled Trial of N-acetylcysteine for the Management of Alcohol Use Disorder

Key facts

Who runs it
University of Sydney
Where
Australia3 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 4
People taking part
280 people, planned
Started
16 Feb 2023
Expected to end
Nov 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • N-acetyl cysteine
  • Placebo
Record updated
16 March 2023

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Alcohol Use Disorder according to the DSM-V criteria
  • A desire to reduce or stop drinking
  • Consumed at least 21 standard drinks per week or 2 heavy drinking days per week (HDD: ≥ 5 standard drinks/day for men; ≥4 for women) in the month prior to screening
  • Adequate cognition and English language skills to give valid consent and complete research interviews
  • Stable housing
  • Willingness to give written informed consent

Who cannot take part

  • Concurrent use of any psychotropic medication other than antidepressants (provided these are taken at stable doses for at least two months)
  • Concurrent use of selenium, vitamin D or other anti-oxidants
  • Clinically unstable systemic medical (e.g. cancer, end stage liver disease: e.g. MELD score ≥ 10) or psychiatric disorder (e.g. active psychosis, borderline personality disorder, active suicide risk: e.g. MADRAS item 10 score of 6) that precludes trial participation
  • Pregnancy or lactation (women will be advised to use reliable contraception during the trial and a pregnancy test will be performed were necessary)
  • Any substance dependence other than nicotine
  • Any alcohol pharmacotherapy within the past month

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To explore the effectiveness of n-acetylcysteine in improving treatment outcomes for alcohol use disorder in a double-blind randomised placebo-controlled trial.

The 2 groups in the trial

  • N-acetyl CysteineTreatment being tested

    Generic name: N-acetyl cysteine. Brand: ACC-600 (Acetylcysteine). Strength: 600mg per capsule. Form: capsule Route: oral Frequency: 2x capsules twice per day = total 4 capsules/day Duration: 12 weeks \+ Standard of Care: Medical Management.

  • PlaceboPlacebo, for comparison

    Matched placebo Generic name: dicalcium phosphate Strength: 600mg per capsule Form: capsule Route: oral Frequency: 2x capsules twice per day = total 4 capsules/day Duration: 12 weeks. \+ Standard of Care: Medical Management.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Fit questions
Built from NCT05408247, who can take part
Publications
Record updated
16 March 2023